Distinct Natural Killer Cell Signature in Still Disease: Insights From a Multinational Immunome Project Consortium for Autoinflammatory Disorders
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.70008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Amber De Visscher und 25 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunobiology, Department of Microbiology, Immunology, and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Bel…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Osteomyelitis, Familial Mediterranean Fever. Die Arbeit nennt 59 Literaturangaben. Gefördert von: Fonds Wetenschappelijk Onderzoek, KU Leuven, European Union Horizon 2020 Research and Innovation Program.
Abstract (Originalsprache)
Objective
Still disease is a rare systemic inflammatory disorder of unknown origin, characterized by episodes of uncontrolled inflammation. Although natural killer (NK) cells have been implicated in Still disease pathogenesis, their precise role remains elusive.
Methods
Within the framework of the Immunome Project Consortium for Autoinflammatory Disorders, we performed a comprehensive NK cell phenotyping in an international cohort comprising 121 patients with distinct systemic autoinflammatory diseases (53 with Still disease, 23 with chronic recurrent multifocal osteomyelitis, 23 with familial Mediterranean fever, and 22 with inflammation of unknown origin) and 32 healthy controls.
Results
Our analysis revealed a unique NK cell signature in Still disease, characterized by a reduction in NK cell frequency and elevated Fas expression, rendering them more susceptible to in vitro Fas ligand–induced apoptosis. Fas ligand was expressed by Still disease monocytes and CD38 + HLA‐DR + cycling lymphocytes. Still disease NK cells displayed a hyperactivated but exhausted phenotype, including cytokine unresponsiveness, all features not observed in the other groups. This NK cell dysfunctional profile was normalized during clinical remission. Exposure of healthy NK cells to interleukin (IL)‐12, IL‐15, and IL‐18 recapitulates the Still disease–associated phenotype, suggesting an inflammation‐driven mechanism. Transcriptomic profiling identified microRNA miR‐146a as a potential regulator of this NK cell dysfunction.
Conclusion
Our findings establish NK cell apoptosis, exhaustion, and cytokine unresponsiveness as defining immunologic features of Still disease, distinguishing it from other inflammatory diseases in this cohort. This dysfunctional NK cell state may underlie the heightened risk of macrophage activation syndrome in Still disease and highlights inflammatory cytokines and miR‐146a as promising therapeutic targets to mitigate disease severity and prevent life‐threatening complications. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Immunobiology, Department of Microbiology, Immunology, and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
- Laboratory for Neuroimmunology, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.
- Laboratory of Adaptive Immunology, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium.
- Laboratory of Molecular Immunology, Department of Microbiology, Immunology, and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
- Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, University of Athens, Athens, Greece.
- Department of Internal Medicine, University Hospital Croix-Rousse, Hospices Civils de Lyon, University of Lyon 1, CIRI, Inserm U1111, ENS/CNRS UMR5308, Lyon Immunopathology Federation, Centre de Référence des Maladies A…
ORCID-Profile: Amber De Visscher, Jarne Beliën, Katerina Laskari, Yvan Jamilloux, Paul Proost, Peter D Katsikis
Förderung
- Fonds Wetenschappelijk Onderzoek
- KU Leuven
- European Union Horizon 2020 Research and Innovation Program
Zitieren
APA
De Visscher, A., Beliën, J., Malengier-Devlies, B., Bernaerts, E., De Vuyst, L., Filtjens, J., Ahmadzadeh, K., Mitera, T., Berghmans, N., Laskari, K., Jamilloux, Y., Regnier, P., Saadoun, D., Girard-Guyonvarc'h, C., Gabay, C., Gouwy, M., Proost, P., Humblet-Baron, S., Mueller, Y. M., …, & Matthys, P. (2026). Distinct Natural Killer Cell Signature in Still Disease: Insights From a Multinational Immunome Project Consortium for Autoinflammatory Disorders. Arthritis & Rheumatology. https://doi.org/10.1002/art.70008
Vancouver
De Visscher A, Beliën J, Malengier-Devlies B, Bernaerts E, De Vuyst L, Filtjens J, et al. Distinct Natural Killer Cell Signature in Still Disease: Insights From a Multinational Immunome Project Consortium for Autoinflammatory Disorders. Arthritis & Rheumatology. 2026. doi:10.1002/art.70008
BibTeX
@article{DeVisscher2026,
author = {De Visscher, Amber and Beliën, Jarne and Malengier-Devlies, Bert and Bernaerts, Eline and De Vuyst, Leana and Filtjens, Jessica and Ahmadzadeh, Kourosh and Mitera, Tania and Berghmans, Nele and Laskari, Katerina and Jamilloux, Yvan and Regnier, Paul and Saadoun, David and Girard-Guyonvarc'h, Charlotte and Gabay, Cem and Gouwy, Mieke and Proost, Paul and Humblet-Baron, Stephanie and Mueller, Yvonne M and Erkland, Stefan J and van de Werken, Harmen J G and Grashof, Dwin G B and Katsikis, Peter D and Immunome Project Consortium for Autoinflammatory Disorders, Immunome Project Consortium for Autoinflammatory Disorders and Wouters, Carine and Matthys, Patrick},
title = {Distinct Natural Killer Cell Signature in Still Disease: Insights From a Multinational Immunome Project Consortium for Autoinflammatory Disorders},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70008}
}
EUVIMED